Abstract: The present invention relates to a pharmaceutical formulation in powder form comprising amoxicillin, cineole and a pharmaceutically acceptable oil. The present formulation may also comprise clavulanic acid. It is intended for oral administration, preferably after suspension in an aqueous solvent. The present invention also relates to a combination of cineole and amoxicillin for use in the treatment of an infectious pathology, preferably a bacterial infection, in an individual. The present combination may also comprise a ?-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention makes it possible in particular to combat infections caused by bacteria that are resistant to antibiotics, preferably to antibiotics of the ?-lactamine family.
Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
Type:
Grant
Filed:
October 13, 2021
Date of Patent:
January 2, 2024
Assignee:
NEUMORA THERAPEUTICS, INC.
Inventors:
Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
Abstract: Provided herein are formulations that can contain an effective amount of a PKC? inhibitor. Also provided herein are methods of inhibiting a PKC? in a subject in need thereof, that can include the step of administering an effective amount of a compound that is capable of inhibiting a PKC?.
Type:
Grant
Filed:
September 13, 2021
Date of Patent:
December 19, 2023
Assignees:
UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Niketa A. Patel, Rekha S. Patel, Robert Pleasants Sparks, Wayne Charles Guida
Abstract: The invention relates to a pharmaceutical formulation comprising nicotine. The formulation can be aerosolised at ambient temperature for delivery via inhalation. The invention also relates to a method of delivering nicotine to a subject via inhalation, and specifically via the use of a nebuliser.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
December 5, 2023
Inventors:
Christopher Nolan, Joseph Kavanagh, Kieran Raleigh, Brian O'Rourke
Abstract: Beta-hydroxybutyric acid compositions for oral delivery are substantially free of beta-hydroxybutyrate salts and are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and/or as a gel or suspension. By excluding beta-hydroxybutyrate salts (e.g., less than 1% by weight) containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid.
Abstract: The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.
Abstract: Disclosed is a method for treating a condition associated with hyperproliferating cells, the method including the steps of administering to a subject having the condition a composition including at least one cannabinoid receptor agonist, optionally administering to the subject a photodynamic compound, and administering radiation to the subject in whom the at least one cannabinoid receptor agonist is present so as to treat the condition.
Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.
Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
October 10, 2023
Assignee:
Duke University
Inventors:
Suzanne E. Wardell, Erik R. Nelson, Donald P McDonnell
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dry eye syndrome and a health functional food composition for preventing or improving dry eye syndrome including ?-humulene as an active ingredient, wherein the ?-humulene improves the expression level of mucin and recovers the reduced amount of tears in the dry eye-induced eye and thus can effectively prevent, improve or treat dry eye syndrome.
Type:
Grant
Filed:
December 28, 2018
Date of Patent:
September 26, 2023
Assignee:
INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
August 22, 2023
Assignee:
Centrexion Therapeutics Corporation
Inventors:
Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
Abstract: Augmented or synergized anti-inflammatory constructs are disclosed including anti-inflammatory terpenes and/or vanilloids covalently conjugated to one another so that the activity of the conjugate is greater than the sum of its parts. Also disclosed are methods of improving the potency of an anti-inflammatory terpene or vanilloid by linking it to another anti-inflammatory terpene or vanilloid via a carbamate linkage, where the potency of the conjugate is greater than the sum of its parts.
Type:
Grant
Filed:
August 12, 2020
Date of Patent:
August 22, 2023
Assignees:
LEHIGH UNIVERSITY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Jeffrey D. Laskin, Diane E. Heck, Carl J. Lacey, Ned D. Heindel, Sherri C. Young
Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.
Type:
Grant
Filed:
September 9, 2021
Date of Patent:
June 27, 2023
Assignee:
GW Research Limited
Inventors:
Colin Stott, Nicholas Jones, Robin Williams, Benjamin Whalley
Abstract: The invention provides a method of inhibiting a TYK2 kinase, which method comprises bringing into contact with the TYK2 kinase an effective TYK2 kinase-inhibiting amount of a compound having the formula (0): or a salt or stereoisomer thereof. The invention also provides a novel subset of compounds within formula (0) as well as pharmaceutical compositions containing them and their use in medicine.
Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
June 6, 2023
Assignee:
EMPIRICO INC.
Inventors:
Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
Abstract: The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.
Type:
Grant
Filed:
November 28, 2017
Date of Patent:
February 28, 2023
Assignee:
PHARMA MAR, S.A.
Inventors:
Victoria Moneo Ocaña, Gema Santamaría Núñez, Luis Francisco García Fernández, Carlos María Galmarini, María José Guillén Navarro, Pablo Manuel Avilés Marín
Abstract: Methods for treating or reducing the likelihood of acquiring estrogen-related (e.g. estrogen-exacerbated) diseases including endometriosis include administering to a patient a selective estrogen receptor modulator (SERM), in combination with inhibiting ovarian secretions, e.g., by administering an LHRH agonist or antagonist. In some embodiments, a precursor of sex steroids, said precursor being selected from the group consisting of dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), androst-5-ene-3?,17?-diol (5 diol), and androstenedione or a compound transformed into one of these, is also administered.
Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
Abstract: The present disclosure relates to methods of using cisplatin active agents in which reduced organ toxicity is observed are provided. In the subject methods, an effective amount is administrated to the host before administration of an effective amount of cisplatin active agents. The cisplatin toxicity reducing agent comprising of stable bismuth(III) complexes or pharmaceutically acceptable salts reduces the levels of undesired toxicity of cisplatin active agents without compromising their anticancer activity. Also provided are methods for use in practicing the subject methods in the treatment of different disease conditions.
Type:
Grant
Filed:
July 14, 2016
Date of Patent:
January 17, 2023
Assignee:
THE UNIVERSITY OF HONG KONG
Inventors:
Hongzhe Sun, Chi-Fung Godfrey Chan, Shing Chan, Runming Wang